Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | GLS | O94925 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8582632 | 1.00 | CYP2C19 (0.53) | CYP2C19CYP2D6SRCLMNAMAPK1 | |
| SCHEMBL8588249 | 0.88 | CYP2C19 (0.50) | CYP2C19CYP2D6SRCLMNAMAPK1 | |
| SCHEMBL8588247 | 0.88 | CYP2C19 (0.50) | CYP2C19CYP2D6SRCLMNAMAPK1 | |
| SCHEMBL30371912 | 0.87 | CYP2C19 (0.61) | CYP2C19CYP2D6SRCLMNAMAPK1 | |
| SCHEMBL6478880 | 0.86 | TBXAS1 (0.51) | CYP2C19CYP2D6SRCLMNAMAPK1 | |
| SCHEMBL8584497 | 0.86 | TBXAS1 (0.51) | CYP2C19CYP2D6SRCLMNAMAPK1 | |
| SCHEMBL28581228 | 0.85 | TBXAS1 (0.54) | CYP2C19CYP2D6SRCLMNAMAPK1 | |
| SCHEMBL76635 | 0.83 | CYP2C19 (0.57) | CYP2C19CYP2D6SRCLMNAMAPK1 | |
| SCHEMBL14360139 | 0.81 | TBXAS1 (0.60) | CYP2C19CYP2D6SRCLMNAMAPK1 | |
| SCHEMBL819393 | 0.81 | CYP2C19 (0.55) | CYP2C19CYP2D6SRCLMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115521404-A | Furanvinylalcohol elastomer based on straw and preparation method thereof | 中国科学院长春应用化学研究所 | 2022-12-27 | — | — | CN | disclosed |
| CN-108752510-B | Iron-catalyzed AGET ATRP system in biomass-based solvent under ligand-free condition and polymerization method | 安徽工程大学 | 2020-05-19 | — | — | CN | disclosed |
| CN-104011043-B | The quinuclidine esters of 1-aza heterocycles guanidine-acetic acid, their preparation method and Pharmaceutical composition thereof as muscarine antagonist | 奇斯药制品公司 | 2016-11-16 | — | — | CN | disclosed |
| CN-106029640-A | Pyrazolone compounds and uses thereof | 因森普深2公司 | 2016-10-12 | — | — | CN | disclosed |
| CN-102947300-B | Alkaloid amino ester derivative and pharmaceutical composition thereof | 奇斯药制品公司 | 2016-09-21 | — | — | CN | disclosed |
| US-7488748-B2 | 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2009-02-10 | — | — | US | disclosed |
| US-20060247225-A1 | 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2006-11-02 | — | — | US | disclosed |
| EP-1590325-A1 | 3,6-DISUBSTITUTED AZABICYCLO HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES, LTD. (IN) | 2005-11-02 | — | — | EP | disclosed |
| WO-2004067510-A1 | 3,6-DISUBSTITUTED AZABICYCLO HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2004-08-12 | — | — | WO | disclosed |
| EP-0782574-B1 | BICYCLIC CARBOXAMIDES AS 5-HT1A RECEPTORS LIGANDS | WYETH JOHN & BROTHER LTD (GB) | 2002-03-27 | — | — | EP | disclosed |
| US-5543419-A | TREATING CHRONIC OBSTRUCTIVE AIRWAYS DISEASE OR ASTHMA; ANTIMUSCARINIC BRONCHODILATOR AGENTS | PFIZER INC (US) | 1996-08-06 | — | — | US | disclosed |
| WO-1996009302-A1 | BICYCLIC CARBOXAMIDES AS 5-HT1A ANTAGONISTS | JOHN WYETH & BROTHER LTD. (GB) | 1996-03-28 | — | — | WO | disclosed |
| EP-0687257-A1 | 4-AMINO-2-(HETERO)ARYL-BUTANAMIDES USEFUL AS 5-HT1A-ANTAGONISTS | WYETH JOHN & BROTHER LTD (GB) | 1995-12-20 | — | — | EP | disclosed |
| EP-0672039-A1 | PROCESS FOR THE PREPARATION OF -g(a)-ARYL--g(g)-BUTYROLACTONES. | WYETH JOHN & BROTHER LTD (GB) | 1995-09-20 | — | — | EP | disclosed |
| WO-1994020481-A1 | 4-AMINO-2-(HETERO)ARYL-BUTANAMIDES USEFUL AS 5-HT1A-ANTAGONISTS | JOHN WYETH & BROTHER LIMITED (GB) | 1994-09-15 | — | — | WO | disclosed |
| EP-0603229-A1 | QUINUCLIDINE ESTERS PROCESS AND INTERMEDIATE FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Pfizer Limited (GB) | 1994-06-29 | — | — | EP | disclosed |
| WO-1994012487-A1 | PROCESS FOR THE PREPARATION OF α-ARYL-η-BUTYROLACTONES | JOHN WYETH & BROTHER LIMITED (GB) | 1994-06-09 | — | — | WO | disclosed |
| CN-1087622-A | The application of cyclohexane derivant, its preparation method and the treatment disease that replaces | HOECHST AG (DE) | 1994-06-08 | — | — | CN | disclosed |
| CN-1070911-A | The treatment compound | PFIZER (US) | 1993-04-14 | — | — | CN | disclosed |
| WO-1993006098-A1 | QUINUCLIDINE ESTERS PROCESS AND INTERMEDIATE FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PFIZER LIMITED (GB) | 1993-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247225-A1 | 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists | CHRM3, CHRM5, CHRM2 | CYP2C19 570/4885CYP2D6 182/4885SRC 2322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.